Studies

Pan Cancer
  • FGFR
Lung Cancer
NSCLC

  • Association between BRAF mutation class and clinical features in BRAF mutant NSCLC
  • EGFR mutant NSCLC treated with EGFR tyrosine kinase inhibitors
  • EGFR L747P Gefitinib and Osimeritinib (Lung adenocarcinoma)
  • ALK G1202L associated with lung adenocarcinoma, Loralatinib
  • EGFR activating mutation T790M/cis-C797S triple mutations for lung adenocarcinoma, brigatinib + cetuximab in combination
  • c-Met Exon 14 Skipping mutations, crizotinib (295 panel)
  • Malignant pleural mesothelioma- multiple mutations including ALKI1171N, ALKL1196M, ALKG1202R, lorlatinib being measured in EML4-ALK rearranged malignant pleural mesothelioma
  • RET rearrangement
  • pulmonary adenoid cystic carcinoma
  • pulmonary blastoma harboring CD74 ROS1 fusion, response to crizotinib
Endometrial Cancer
  • afatinib in HER2 positive endometrioid adenocarcinoma
Colorectal cancer (295 panel)
  • somatic pole exonuclease domain mutations
Gallbladder cancer
  • AMBER1 – ALK fusion, crizotinib
Breast cancer
  • metastatic breast cancer
  • HER2 positive breast cancer, heterogeneity of genomic profile
  • BRCA vs NonBRCA germline and somatic mutations
Cervical
  • EGFR amplification cervical squamous cell carcinoma with pulmonary metastasis, afatinib
  • metastatic cervical carcinoma with high-TMB, exceptional response of cryo ablation followed by pembrolizumab
Metastasis
  • mutational signal of double primary malignancies
Brain Cancer
  • pleomorphic xanthoastrocytoma
Metastatic Nasopharyngeal Carcinoma
  • CDK4 amplification, palbociclib